Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia in Patients: A Comparison between Silodosin and Tadalafil

Abstract

Background: Benign prostatic hyperplasia (BPH) is a highly prevalent and a very common disease in elderly men. LUTS secondary to BPH increases with age and has a negative impact on patient’s quality of life. LUTS associated with BPH has variety of interventional treatment options like medical management and surgical management, where α1 blockers are tried as first line either alone or in combination with 5-α reductase inhibitors. The aim of our study is to compare the therapeutic efficacy of silodosin with tadalafil over a period of 4 weeks. Methods: A prospective, observational, hospital based study. A total of 136 patients were involved in this study. 68 patients received silodosin 8 mg once daily and 68 patients received tadalafil 5 mg once daily as decided by the Urologist . At the end of 4th week the therapeutic efficacy of both the drugs were assessed by IPSS, IPSS QoL index score and OABSS. Adverse drug reaction in each group were also noted. Results: Both silodosin and tadalafil were statistically significant in decreasing total IPSS, IPSS QoL index score and total OABSS at end of 4th week. But silodosin produced statistically significant reduction in total IPSS and IPSS QoL index score when compared to tadalafil. Silodosin produced numerically greater but statistically not significant reduction in total OABSS when compared to tadalafil. Incidence of adverse effects were more in silodosin group. Conclusion: In our study we noted that both silodosin and tadalafil were efficacious in treating LUTS associated with BPH but silodosin was superior to tadalafil. Tadalafil is efficacious in patients with concomitant ED.